CLINICAL STUDIES
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions
Steven R. Steinhubl, MD*  ,
Michael S. Lauer, MD, FACC*,
Debabrata P. Mukherjee, MD*,
David J. Moliterno, MD, FACC*,
A. Michael Lincoff, MD, FACC*,
Stephen G. Ellis, MD, FACC* and
Eric J. Topol, MD, FACC*
* Department of Cardiology and Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Department of Medicine, Ohio State University, Cleveland, Ohio, USA
Manuscript received April 17, 1998;
revised manuscript received June 19, 1998,
accepted July 6, 1998.
Address for correspondence: Dr. Michael S. Lauer, Department of Cardiology, Desk F-25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195
lauerm{at}cesmtp.ccf.org
Objectives. This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non–Q-wave myocardial infarctions (MIs).
Background. Dual antiplatelet therapy with ticlopidine and aspirin is routinely used with stenting, although ticlopidine is commonly not begun until the day of the procedure. Periprocedural MIs are at least partially platelet-dependent events. As the maximal platelet inhibitory effects of this drug take 2 to 3 days to be realized, we hypothesized that longer treatment prior to stenting would be associated with lower rates of procedure-related MIs.
Methods. We reviewed outcomes in 175 consecutive patients treated with ticlopidine prior to stenting at the Cleveland Clinic Foundation. Those patients with an elevation in creatine kinase above our laboratory normal (>210 IU/L) with  4% MB fraction on routine evaluation were defined as having a non–Q-wave MI.
Results. There were 28 patients (16%) who had a non–Q-wave MI. Longer duration of ticlopidine pretreatment was strongly associated with a lower incidence of procedure-related non–Q-wave MIs (duration of pretreatment <1 day, 29% had MI; 1 to 2 days, 14%; 3 days, 5%; chi-square for trend = 9.6; p = 0.002). Ticlopidine pretreatment of 3 days was associated with a significant reduction in the risk of non–Q-wave MI (unadjusted odds ratio 0.18, 95% confidence interval = 0.04 to 0.78, p = 0.01) compared with pretreatment of <3 days.
Conclusions. Among patients undergoing intracoronary stenting, beginning ticlopidine therapy several days prior to the procedure is associated with a reduced risk of procedural non–Q-wave MIs.
|
Abbreviations and Acronyms
| | ADP | = adenosine diphosphate | | GPIIb/IIIa | = glycoprotein IIb/IIIa | | PTCA | = percutaneous transluminal coronary angioplasty |
|
This article has been cited by other articles:
|
|
|
|
 
C. Briguori, G. Visconti, A. Focaccio, B. Golia, A. Chieffo, A. Castelli, M. Mussardo, M. Montorfano, B. Ricciardelli, and A. Colombo
Novel Approaches for Preventing or Limiting Events (Naples) II Trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction
J. Am. Coll. Cardiol.,
August 5, 2009;
(2009)
j.jacc.2009.07.005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell
The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
299S - 339S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hamdalla and S. R. Steinhubl
Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_G):
G20 - G24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl and R. Charnigo
Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
JAMA,
April 5, 2006;
295(13):
1581 - 1582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R V Kelly and S Steinhubl
Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention
Heart,
June 1, 2005;
91(suppl_3):
iii16 - iii19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Claeys, M. G. Van der Planken, J. M. Bosmans, J. J. Michiels, F. Vertessen, P. Van Der Goten, F. L. Wuyts, and C. J. Vrints
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis
Eur. Heart J.,
March 2, 2005;
26(6):
567 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Briguori, A. Colombo, F. Airoldi, A. Violante, A. Focaccio, P. Balestrieri, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, et al.
Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction
Eur. Heart J.,
October 2, 2004;
25(20):
1822 - 1828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. van der Heijden, I. C. D. Westendorp, R. K. Riezebos, F. Kiemeneij, T. Slagboom, L. R. van der Wieken, and G.-J. Laarman
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
20 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Stadius
Diminishing returns ...and too many choices ...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
25 - 27.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment
J. Am. Coll. Cardiol.,
March 17, 2004;
43(6):
1122 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, J. Mehilli, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, H. Bollwein, C. Volmer, M. Gawaz, et al.
A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel
N. Engl. J. Med.,
January 15, 2004;
350(3):
232 - 238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ross, H. C. Herrmann, D. J. Moliterno, J. C. Blankenship, L. Demopoulos, P. M. DiBattiste, S. G. Ellis, Z. Ghazzal, J. L. Martin, J. White, et al.
Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition: Results from the TARGET trial
J. Am. Coll. Cardiol.,
September 17, 2003;
42(6):
981 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. Levine, M. J. Kern, P. B. Berger, D. L. Brown, L. W. Klein, D. J. Kereiakes, T. A. Sanborn, A. K. Jacobs, and for the American Heart Association Diagnostic and
Management of Patients Undergoing Percutaneous Coronary Revascularization
Ann Intern Med,
July 15, 2003;
139(2):
123 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl, P. B. Berger, J. T. Mann III, E. T. A. Fry, A. DeLago, C. Wilmer, E. J. Topol, and for the CREDO Investigators
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial
JAMA,
November 20, 2002;
288(19):
2411 - 2420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Berger and S. Steinhubl
Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study: A US Perspective
Circulation,
October 22, 2002;
106(17):
2284 - 2287.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, D. J. Moliterno, M. Bertrand, F.-J. Neumann, H. C. Herrmann, E. R. Powers, C. L. Grines, J. W. Moses, D. J. Cohen, E. A. Cohen, et al.
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial*
Circulation,
May 21, 2002;
105(20):
2347 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al.
ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
J. Am. Coll. Cardiol.,
June 15, 2001;
37(8):
2239 - 2239.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, and E. J. Topol
Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events : Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
Circulation,
March 13, 2001;
103(10):
1403 - 1409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Kaluza, J. Joseph, J. R. Lee, M. E. Raizner, and A. E. Raizner
Catastrophic outcomes of noncardiac surgery soon after coronary stenting
J. Am. Coll. Cardiol.,
April 1, 2000;
35(5):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Topol and J. S. Yadav
Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease
Circulation,
February 8, 2000;
101(5):
570 - 580.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Quinn and D. J. Fitzgerald
Ticlopidine and Clopidogrel
Circulation,
October 12, 1999;
100(15):
1667 - 1672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
